Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of “Reduce” by Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been assigned an average rating of “Reduce” from the six brokerages that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating and three have given a hold rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $12.75.

Several brokerages have recently weighed in on IART. Argus restated a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup upped their target price on shares of Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a research note on Wednesday, May 6th. Finally, Truist Financial decreased their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Global Retirement Partners LLC bought a new position in Integra LifeSciences during the 4th quarter valued at $25,000. Osaic Holdings Inc. boosted its stake in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares during the last quarter. GAMMA Investing LLC boosted its stake in Integra LifeSciences by 145.9% during the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after acquiring an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Integra LifeSciences during the 4th quarter valued at $124,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Down 0.1%

NASDAQ:IART opened at $15.10 on Friday. The firm has a market capitalization of $1.17 billion, a PE ratio of -2.34, a price-to-earnings-growth ratio of 1.05 and a beta of 1.08. The business’s 50-day moving average is $11.10 and its two-hundred day moving average is $11.69. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $16.49.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13. The business had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Research analysts predict that Integra LifeSciences will post 2.44 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.